ASEM 문헌 요약
Official Canadian Paediatric Society document (2023) on “Inhaled nitric oxide use in newborns”. Inhaled nitric oxide (iNO), a selective pulmonary vasodilator, is used as a therapeutic modality in infants with hypoxemic respiratory failure (HRF) associated with persistent pulmonary hypertension of the newborn (PPHN). iNO should ideally be initiated following echocardiographic confirmation of PPHN. Use of iNO is recommended in late preterm and term infants who develop HRF despite optimal oxygenation and ventilati.
이 요약은 문서를 식별하는 데 도움이 됩니다. 임상 권고사항은 항상 공식 버전과 업데이트 날짜를 확인하십시오.
공식 문서